Treatment of pemphigus vulgaris and foliaceus with efgartigimod, a neonatal Fc receptor inhibitor: a phase II multicentre, open‐label feasibility trial *

Pemphigus vulgaris and pemphigus foliaceus are potentially life‐threatening autoimmune disorders triggered by IgG autoantibodies against mucosal and epidermal desmogleins. There is an unmet need for fast‐acting drugs that enable patients to achieve early sustained remission with reduced corticosteroid reliance.

[1]  V. Werth,et al.  Safety, Tolerability, and Activity of ALXN1830 Targeting the Neonatal Fc Receptor in Chronic Pemphigus. , 2021, The Journal of investigative dermatology.

[2]  K. Kridin,et al.  Epidemiology of Pemphigus , 2021, JID innovations.

[3]  R. Bergman,et al.  Updated S2K guidelines on the management of pemphigus vulgaris and foliaceus initiated by the european academy of dermatology and venereology (EADV) , 2020, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  D. Zillikens,et al.  S2k guidelines for the treatment of pemphigus vulgaris/foliaceus and bullous pemphigoid: 2019 update , 2020, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

[5]  H. de Haard,et al.  Phase 2 study of efgartigimod, a novel FcRn antagonist, in adult patients with primary immune thrombocytopenia , 2019, American journal of hematology.

[6]  L. Pearce,et al.  Blocking FcRn in humans reduces circulating IgG levels and inhibits IgG immune complex–mediated immune responses , 2019, Science Advances.

[7]  P. van Damme,et al.  Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis , 2019, Neurology.

[8]  L. Misery,et al.  Incidence and Mortality of Pemphigus in France. , 2019, The Journal of investigative dermatology.

[9]  R. Ober,et al.  Neonatal Fc receptor antagonist efgartigimod safely and sustainably reduces IgGs in humans , 2018, The Journal of clinical investigation.

[10]  H. Shimizu,et al.  Diagnosis and Management of Pemphigus: recommendations by an International Panel of Experts. , 2018, Journal of the American Academy of Dermatology.

[11]  M. Mustapa,et al.  British Association of Dermatologists’ guidelines for the management of pemphigus vulgaris 2017 , 2017, The British journal of dermatology.

[12]  L. Misery,et al.  First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): a prospective, multicentre, parallel-group, open-label randomised trial , 2017, The Lancet.

[13]  E. Schmidt.  Rituximab as first-line treatment of pemphigus , 2017, The Lancet.

[14]  N. Chainani-Wu,et al.  Management of Pemphigus Vulgaris , 2016, Advances in Therapy.

[15]  J. Roujeau,et al.  Long-Term Remissions of Severe Pemphigus After Rituximab Therapy Are Associated with Prolonged Failure of Desmoglein B Cell Response , 2013, Science Translational Medicine.

[16]  R. Corona,et al.  Therapy with rituximab for autoimmune pemphigus: results from a single-center observational study on 42 cases with long-term follow-up. , 2012, Journal of the American Academy of Dermatology.

[17]  Z. Apalla,et al.  High dose oral prednisone vs. prednisone plus azathioprine for the treatment of oral pemphigus: a retrospective, bi‐centre, comparative study , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[18]  D. Zillikens,et al.  Immunoadsorption in dermatology , 2010, Archives of Dermatological Research.

[19]  A. Troxel,et al.  Reliability and convergent validity of two outcome instruments for pemphigus. , 2009, The Journal of investigative dermatology.

[20]  H. Shimizu,et al.  A randomized double-blind trial of intravenous immunoglobulin for pemphigus. , 2009, Journal of the American Academy of Dermatology.

[21]  R. Ober,et al.  Chapter 4: Multitasking by exploitation of intracellular transport functions the many faces of FcRn. , 2009, Advances in immunology.

[22]  H. Shimizu,et al.  Consensus statement on definitions of disease, end points, and therapeutic response for pemphigus. , 2008, Journal of the American Academy of Dermatology.

[23]  J. Andersen,et al.  Dependence of antibody-mediated presentation of antigen on FcRn , 2008, Proceedings of the National Academy of Sciences.

[24]  G. Vidarsson,et al.  FcRn: an IgG receptor on phagocytes with a novel role in phagocytosis. , 2006, Blood.

[25]  Masayuki Amagai,et al.  Pemphigus, bullous impetigo, and the staphylococcal scalded-skin syndrome. , 2006, The New England journal of medicine.

[26]  D. Roopenian,et al.  Complete FcRn dependence for intravenous Ig therapy in autoimmune skin blistering diseases. , 2005, The Journal of clinical investigation.

[27]  R. Ober,et al.  Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels , 2005, Nature Biotechnology.

[28]  K. Wolff,et al.  Expression of FcRn, the MHC class I-related receptor for IgG, in human keratinocytes. , 2005, The Journal of investigative dermatology.

[29]  Raimund J. Ober,et al.  Visualizing the Site and Dynamics of IgG Salvage by the MHC Class I-Related Receptor, FcRn1 , 2004, The Journal of Immunology.

[30]  M. Pittelkow,et al.  Pemphigus Vulgaris IgG and Methylprednisolone Exhibit Reciprocal Effects on Keratinocytes* , 2004, Journal of Biological Chemistry.

[31]  E. Bröcker,et al.  Protein A immunoadsorption: a novel and effective adjuvant treatment of severe pemphigus , 2003, The British journal of dermatology.

[32]  D. Pearl,et al.  The Major Histocompatibility Complex–related Fc Receptor for IgG (FcRn) Binds Albumin and Prolongs Its Lifespan , 2003, The Journal of experimental medicine.

[33]  K. V. Ratnam,et al.  Pemphigus Therapy with Oral Prednisolone Regimens A 5‐Year Study , 1990, International journal of dermatology.